Norvasc

Norvasc
Name	Norvasc
Tradename	Norvasc
Generic name	amlodipine
Class	Calcium channel blocker
Routes of administration	Oral
Legal status	Prescription-only
Bioavailability	~64–90%
Metabolism	Hepatic (CYP3A4)
Elimination half-life	~30–50 hours
Excretion	Urine

Norvasc Norvasc is the brand name for the antihypertensive and antianginal medication amlodipine, produced by Pfizer. It is primarily used to treat high blood pressure and chronic stable angina and is included on many national formularies and clinical guidelines. The drug has been the subject of clinical trials, regulatory approvals, patent litigation, and wide international use.

Medical uses

Amlodipine is indicated for the management of essential hypertension and for symptomatic treatment of chronic stable angina and vasospastic angina (Prinzmetal angina). Clinical trial data from multicenter studies and randomized controlled trials conducted in populations represented in the cohorts of the Framingham Heart Study, Allied Dunbar Primary Care Research Network, and trials sponsored in collaboration with institutes such as the National Heart, Lung, and Blood Institute informed guideline recommendations by organizations including the American Heart Association, European Society of Cardiology, and national health services like the National Health Service (England). It is also used off-label for conditions such as Raynaud's phenomenon and certain variants of cerebral vasospasm documented in reports from institutions like Mayo Clinic and Cleveland Clinic.

Pharmacology

Amlodipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels on vascular smooth muscle, producing vasodilation of peripheral arteries and decreased systemic vascular resistance. Pharmacokinetic and pharmacodynamic characterization was performed in pharmacology labs collaborating with universities such as Harvard University, Johns Hopkins University, and University of Oxford. It undergoes hepatic metabolism primarily via the cytochrome P450 enzyme system, notably CYP3A4, with metabolites excreted in urine. The drug’s long elimination half-life underpins once-daily dosing, a feature emphasized in reviews published in journals associated with institutions like The Lancet and New England Journal of Medicine.

Dosage and administration

Typical initiation regimens follow product labeling and dosing recommendations consistent with trials overseen by regulatory agencies such as the Food and Drug Administration and the European Medicines Agency. Adult antihypertensive dosing often begins at 2.5–5 mg once daily, with maintenance doses ranging up to 10 mg once daily; dosing for angina generally follows similar ranges. Dose adjustments are recommended for patients with hepatic impairment and for elderly patients, with guidance referenced in formularies like the British National Formulary and prescribing compendia from organizations including the World Health Organization. Amlodipine is administered orally and may be combined in fixed-dose combinations with agents from classes represented by drugs produced by manufacturers such as Bayer, Novartis, and Sanofi.

Side effects and contraindications

Common adverse effects include peripheral edema, flushing, headache, and palpitations; these adverse events were reported in pivotal trials conducted in cohorts described in reports by centers including Massachusetts General Hospital and Stanford University Medical Center. Less frequent but serious reactions include hypotension, exacerbation of angina upon initiation in some patients with severe obstructive coronary disease, and rare hypersensitivity reactions; cardiology case series from institutions such as Mount Sinai Hospital and Johns Hopkins Hospital document such occurrences. Contraindications and precautions align with labeling decisions by agencies like the FDA and EMA, with caution advised in patients with severe aortic stenosis and significant hepatic dysfunction; monitoring strategies reflect standards promulgated by professional societies including the American College of Cardiology.

Interactions

Amlodipine’s metabolism via CYP3A4 predisposes to interactions with strong inhibitors and inducers of that enzyme, including agents developed by companies and institutions involved in drug research such as Pfizer, Roche, and GlaxoSmithKline; clinical interaction warnings reference specific drugs like certain macrolide antibiotics and azole antifungals. Concomitant use with other antihypertensive agents—beta blockers produced by manufacturers like AstraZeneca or ACE inhibitors used widely after landmark trials at centers such as Vanderbilt University—can produce additive blood-pressure lowering effects and are routinely used in combination therapy according to guidelines from the European Society of Hypertension. Interactions with grapefruit juice, a subject of nutritional pharmacology studies at universities like UC Berkeley and University of Florida, may increase systemic exposure and are noted in patient counseling information.

History and society

Amlodipine was developed in the 1980s and became a major product for its originator corporation; its clinical development, patent filings, and marketing involved collaborations among pharmaceutical research units and regulatory submissions to bodies including the Food and Drug Administration and national agencies in countries represented by ministries such as the Ministry of Health (United Kingdom). The drug’s patent expirations prompted generic competition from firms like Teva Pharmaceutical Industries, Sun Pharma, and Mylan, leading to litigation and settlements similar to intellectual property disputes seen in cases involving companies such as Pfizer and Novartis. Its inclusion on essential medicines lists and widespread prescribing influenced health policy discussions in venues including the World Health Organization and national health authorities such as the Centers for Medicare & Medicaid Services. Public health analyses by think tanks and academic centers including Brookings Institution and Harvard Medical School have addressed cost, access, and the role of amlodipine-containing regimens in population-based cardiovascular risk reduction programs modeled after initiatives from the Global Burden of Disease study.

Category:Antihypertensive agents